ANCN - Anchiano Therapeutics slumps 15% WeissLaw continues investigations

Weissaw is investigating possible breaches of fiduciary duty and other violations of law by Anchiano Therapeutics ([[ANCN]] -16.0%) in connection with the proposed merger with Chemomab.Anchiano to combine with Chemomab via a reverse-merger to create a public company focused on advancing Chemomab's lead product, CM-101.Weissaw is investigating whether Anchiano's board acted in the best interest of shareholders over the proposed transaction in terms of valuation and information disclosed.

For further details see:

Anchiano Therapeutics slumps 15%, WeissLaw continues investigations